KR
Therapeutic Areas
Olema Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Palazestrant (OP-1250) | ER+/HER2- metastatic breast cancer (2L+) | Phase 3 |
| OP-1250 combination studies | ER+/HER2- metastatic breast cancer with various agents | Phase 1b/2 |
| OP-3136 | Undisclosed women's cancers | Preclinical |
Leadership Team at Olema Pharmaceuticals
SP
Sean P. Bohen
President and Chief Executive Officer
SK
Shane Kovacs
Chief Financial Officer and Chief Business Officer
DC
David C. Myles
Chief Development Officer
PK
Pamela Klein
Chief Medical Officer
CH
Cyrus Harmon
Founder and Chief Scientific Officer
GJ
G. Jonah R. Rainey
Senior Vice President, Corporate Development and Strategy
NZ
Naseem Zojwalla
Senior Vice President, Clinical Development
LM
Lori M. Kunkel
Former Acting Chief Medical Officer and Board Member
DB
David B. Singer
Chairman of the Board
IM
Isaac M. Ciechanover
Board Member